See more : Adamant DRI Processing and Minerals Group (ADMG) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Orient Gene Biotech Co., Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- DSwiss, Inc. (DQWS) Income Statement Analysis – Financial Results
- ArcPacific Resources Corp. (ACP.V) Income Statement Analysis – Financial Results
- Broadscale Acquisition Corp. (SCLEW) Income Statement Analysis – Financial Results
- Canox Corporation (8076.T) Income Statement Analysis – Financial Results
- China Mobile Limited (0941.HK) Income Statement Analysis – Financial Results
Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
About Zhejiang Orient Gene Biotech Co., Ltd.
Zhejiang Orient Gene Biotech Co., Ltd. researches and develops, produces, and sells colloidal gold tests, urinalysis strips, raw materials, instruments, and molecular diagnosis products primarily in China. Its products include genetic diagnosis products; colloidal gold rapid diagnostic tests for drugs of abuse, infectious diseases, fertility, cardiac and tumor markers, and autoimmunity; dry chemical strips; bio-liquid diagnostic kits; clinical test instruments; POCT time-resolved fluor immunoassay test kits; raw materials; etc. The company also exports its products to North and South America, Europe, South Asia, Southeast Asia, the Middle East, Africa, Russia, and Australia. Zhejiang Orient Gene Biotech Co., Ltd. was founded in 2005 and is based in Huzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 820.16M | 8.77B | 10.17B | 3.27B | 367.38M | 285.89M | 224.24M | 182.26M |
| Cost of Revenue | 467.40M | 4.31B | 2.67B | 677.78M | 192.85M | 146.75M | 116.33M | 94.62M |
| Gross Profit | 352.75M | 4.45B | 7.50B | 2.59B | 174.52M | 139.15M | 107.91M | 87.63M |
| Gross Profit Ratio | 43.01% | 50.79% | 73.79% | 79.24% | 47.51% | 48.67% | 48.12% | 48.08% |
| Research & Development | 260.86M | 511.56M | 428.52M | 93.75M | 31.76M | 18.64M | 12.30M | 9.26M |
| General & Administrative | 127.47M | 115.80M | 55.39M | 18.52M | 11.57M | 8.94M | 20.53M | 11.59M |
| Selling & Marketing | 162.19M | 485.11M | 1.04B | 317.40M | 28.80M | 25.53M | 22.14M | 19.71M |
| SG&A | 289.66M | 600.92M | 1.09B | 335.92M | 40.37M | 34.47M | 42.67M | 31.30M |
| Other Expenses | 186.07M | 219.88M | 98.77M | 33.60M | 7.93M | 1.84M | 2.60M | 3.48M |
| Operating Expenses | 736.59M | 1.33B | 1.62B | 463.27M | 80.06M | 65.07M | 56.24M | 42.53M |
| Cost & Expenses | 1.20B | 5.65B | 4.29B | 1.14B | 272.91M | 211.82M | 172.57M | 137.15M |
| Interest Income | 207.67M | 116.84M | 34.87M | 4.95M | 468.37K | 481.09K | 0.00 | 2.48M |
| Interest Expense | 18.12M | 6.97M | 936.30K | 44.61K | 1.70M | 3.65M | 3.43M | 6.66M |
| Depreciation & Amortization | 165.49M | 95.07M | 39.57M | 9.11M | 7.37M | 6.71M | 5.49M | 4.71M |
| EBITDA | -199.98M | 2.56B | 5.81B | 1.98B | 101.52M | 88.21M | 48.32M | 56.27M |
| EBITDA Ratio | -24.38% | 42.96% | 57.61% | 63.97% | 28.04% | 31.25% | 22.49% | 32.29% |
| Operating Income | -658.18M | 3.68B | 5.78B | 1.97B | 91.03M | 75.16M | 37.22M | 40.32M |
| Operating Income Ratio | -80.25% | 41.97% | 56.80% | 60.46% | 24.78% | 26.29% | 16.60% | 22.12% |
| Total Other Income/Expenses | 253.95M | -57.46M | -6.43M | -64.71K | 263.39K | 1.84M | 2.60M | 3.48M |
| Income Before Tax | -404.23M | 2.47B | 5.77B | 1.97B | 91.30M | 77.00M | 39.82M | 43.80M |
| Income Before Tax Ratio | -49.29% | 28.18% | 56.74% | 60.46% | 24.85% | 26.93% | 17.76% | 24.03% |
| Income Tax Expense | 14.04M | 373.32M | 829.32M | 293.95M | 13.79M | 13.04M | 7.11M | 8.17M |
| Net Income | -397.58M | 2.07B | 4.92B | 1.68B | 82.11M | 65.37M | 33.36M | 35.63M |
| Net Income Ratio | -48.48% | 23.58% | 48.38% | 51.37% | 22.35% | 22.87% | 14.88% | 19.55% |
| EPS | -1.97 | 12.31 | 34.17 | 8.50 | 0.54 | 0.43 | 0.22 | 0.40 |
| EPS Diluted | -1.97 | 12.31 | 34.17 | 8.50 | 0.54 | 0.43 | 0.22 | 0.40 |
| Weighted Avg Shares Out | 201.82M | 167.97M | 144.01M | 197.34M | 151.57M | 150.44M | 148.53M | 90.15M |
| Weighted Avg Shares Out (Dil) | 201.82M | 167.97M | 144.01M | 197.34M | 151.58M | 150.44M | 151.46M | 90.15M |
Source: https://incomestatements.info
Category: Stock Reports